The SGLT2 HYPE Team

About this partner

The University Medical Center Schleswig-Holstein (UKSH) is one of the largest university hospitals in Germany and among the most advanced medical centers in Europe. With approximately 2,600 inpatient beds and more than 16,000 employees, UKSH provides comprehensive medical care across all specialties. It operates on two campuses, in Kiel and Lübeck, and is affiliated with both the University of Lübeck and the University of Kiel. UKSH combines cutting-edge patient care with internationally recognized research and academic training. Its strategic research priorities include cardiovascular medicine, oncology, neurosciences, and infection research, supported by state-of-the-art infrastructure and a strong network of national and international collaborations

Role in the project

As the sponsor and coordinating institution of the SGLT2 HYPE trial, the University Medical Center Schleswig-Holstein (UKSH) plays a central and leading role in the implementation of this large-scale, multicountry initiative. UKSH is responsible for the overall trial governance, including regulatory submissions, pharmacovigilance, monitoring oversight (via subcontractor), and the procurement and distribution of investigational medicinal products and blood pressure monitoring devices. The trial’s clinical database and electronic case report forms (eCRF) are also developed and maintained under the leadership of UKSH. UKSH hosts the trial’s coordinating investigators and contributes extensive clinical trial experience through its cardiology department in Lübeck. UKSH has access to an established high-performing trial site network, facilitating rapid and high-quality patient recruitment across Europe. The institution also provides key infrastructure for imaging data management (DICOM), supports the development of a biobank framework according to BBMRI-ERIC standards, and ensures adherence to FAIR data principles. Additionally, UKSH leads multiple work packages (WP1, WP2, WP6, WP7, WP14) and coordinates the submission of de-identified datasets to the European Open Science Cloud (EOSC), enabling secondary analyses and long-term data reuse.

Team

• Prof. Dr. Ingo Eitel
• Dr. Elias Rawish
• Dr. Roza Saraei
• Prof. Dr. Thomas Stiermaier
• Dr. Tobias Graf
• PD. Dr. Christina Paitazoglou
• Dr. Matthias Mezger

About this partner

The Medical University of Innsbruck has some 2000 employees (more than 1250 researchers) and about 3,400 students. Together with the University of Innsbruck it is the largest centre of training and research in Western Austria and sees itself as the home university for students from the Tyrol, Vorarlberg, Alto Adige (Südtirol) and Liechtenstein. The Medical University of Innsbruck offers the following courses of studies: Medicine and Dentistry as a basis for academic medical training and PhD courses for graduates who wish to consolidate their scientific skills. A new bachelor course in Molecular Medicine was added to the programme in autumn 2011. Furthermore, graduates of Medicine or Dentistry can continue their studies with a Clinical PhD in tandem with work.

The Medical University of Innsbruck is involved in numerous international training and research programmes and is integrated into various networks. Research focuses on the fields of Oncology, Neurosciences, Genetics, Epigenetics and Genomics as well as Infectiology, Immunology & Organ and Tissue Transplant. In addition, researchers at the Medical University of Innsbruck assert themselves well in the extremely competitive field of funding and are very successful both on a national and international scale.

Role in the project

The Medical University of Innsbruck plays a pivotal role in the SGLT2 HYPE project, serving as the national lead for patient recruitment in Austria. As the Country Principal Investigator site, MUI is responsible for overseeing and coordinating all participating Austrian recruitment centres contributing to the trial and also will support the development of a patient recruitment strategy (WP12).

In addition, MUI leads Work Package 3 (WP3): Enabling Direct Patient Involvement through eHealth. This work package is dedicated to the development of a patient-centred mobile application designed to support home blood pressure monitoring (HBPM) and the collection of quality-of-life (QoL) data. The app will be interactive and intuitive, enabling participants to log their blood pressure from home and complete routine questionnaires. Real-time data sharing and automated reminders will further enhance patient engagement and data accuracy.

Team

• Prof. Dr. Sebastian Reinstadler
• Dr. Ivan Lechner, PhD
• Dr. Christina Tiller, PhD
• Prof. Dr. Axel Bauer

About this partner

The General University Hospital in Prague (VFNP) is one of the largest and most advanced healthcare facilities in the Czech Republic. It provides basic, specialized, and highly specialized care across all core medical disciplines for both adults and children, along with comprehensive pharmaceutical services, including the preparation of cytostatics and sterile medications.

VFNP is the main teaching hospital of the 1st Faculty of Medicine at Charles University and a leading scientific institution in the country. With a history dating back to 1790, it holds the longest tradition of academic medicine and remains the largest medical research center in the Czech Republic.

The 2nd Department of Internal Medicine – Department of Cardiology and Angiology is part of the VFNP’s COMPLEX CARDIOVASCULAR CENTRE, delivering advanced cardiovascular care to around 40,000 patients annually. These include cases of coronary heart disease, valvular defects, cardiomyopathies, arrhythmias, pulmonary hypertension, and vascular diseases.

The department treats many acute cases (e.g., myocardial infarction, cardiac arrest, cardiogenic shock) in its three specialized intensive care units and 24/7 catheterization labs. Outpatient care is offered through dedicated centers and clinics for heart failure, vascular diseases, valvular disorders, pulmonary hypertension, echocardiography, and cardiac pacing.

Role in the project

VFNP (2^nd Department of Internal Medicine – Department of Cardiology and Angiology) will participate in the consortium in enrolling, treatment and follow up of patients in the Czech Republic (WP6, WP15, WP20, WP25, WP30) during the project and for collecting biological samples (serum, plasma, urine) for molecular and proteomic analyses that will contribute to the elucidation of basic biological processes affected by SGLT2i treatment in HTN (WP4). The samples collected will help to identify biomarkers and their impact on cardiovascular outcome in HTN, heart failure progression and cardiac remodelling. VFNP will also contribute to providing data for cost-effectiveness and health-economic analyses (WP9) and will also support the development of a patient recruitment strategy (WP12).

Team

• Prof. MD. Jan Bělohlávek
• Assoc. Prof. MD. Vladimír Tuka
• MD. Jana Podzimková
• MD. Eduard Němeček

About this partner

Arttic Innovation GmbH, a company of the PNO Consultants Group, the European leader in collaboration engineering, consultancy and management services for international research and technology related partnerships. The team at Arttic Innovation has been built since 2006 and has set up and managed numerous projects in EU funding programmes. Arttic Innovation builds and assists collaborative undertakings and in particular European research consortia and networks from all businesses and research sectors, small and large, private and public, to ensure their collaborative innovation ventures are as successful as possible. The service offer of Arttic Innovation comprises provision of hands-on support, strategic consulting, and added value services all along the innovation life cycle: from the definition of a project idea and concept, the identification of a suitable funding scheme and the proposal development, to the management of the project and the dissemination and exploitation of the project results.

Role in the project

Arttic Innovation supports the consortium in the daily management and administrative tasks (WP14) to ensure the collaboration is working efficiently, the project is properly monitored, and decisions and actions are prepared and taken according to the project progress. Arttic Innovation provides methods, tools and operational support for the collaboration within the consortium and simplifies the work of the Research, Development and Innovation staff as much as possible. In addition, Arttic Innovation leads WP13 (Dissemination and Communication) with planning and facilitating of a dissemination, communication and exploitation strategy and developing the adequate tools to support these activities.

 Team

• Dr. Monika Maaß
• Dr. Melanie Carevic-Neri
• MSc. Visar Demiri

About this partner

The Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. German Cardiac Society (DGK), based in Düsseldorf, was founded on 3 June 1927 and is thus the oldest and largest cardiological society in Europe. It is a non-profit scientific medical association with more than 13,000 members that brings together cardiologists from universities and non-university institutions, practising cardiologists, paediatric cardiologists, heart surgeons, scientists working in the field of cardiology, internists, pharmacologists, physiologists, pathologists and biologists, in order to promote science in the field of cardiovascular diseases, provide training and further education for its members, and draw up guidelines.

The DGK publishes five journals: Basic Research in Cardiology, Clinical Research in Cardiology, Der Kardiologe, Herzschrittmacher + Elektrophysiologie, Cardio News and organizes conferences, the largest of which, is annually visited by more than 8,500 experts.

However, the DGK is also internationally active, e.g. through its memberships at the World Heart Federation, the European Society of Cardiology and European Union of Medical Specialists (UEMS: Union Européenne des Médecins Spécialistes).

Role in the project

The DGK, in collaboration with PNO Innovation, UKSH, and DHS, will support the development of a tailored dissemination and communication strategy to ensure the effective sharing of the project’s objectives, progress, and research outcomes with key stakeholder groups. Furthermore, the DGK is involved in continuous feedback loop throughout the trial to enhance the trial’s relevance to clinical guidelines, daily practice, and health policy and will attend be a guideline stakeholder meeting for discussing the study data, formulating recommendations for guideline revisions, and facilitating consensus discussions among experts.

Team

• Prof. Dr. Stephan Baldus
• LL.M. Julia Anne Bernard
• Kerstin Kacmaz
• Marc Pfeil
• MSc. Marie Zečević

About this partner

The German Heart Foundation (GHF; Deutsche Herzstiftung e. V.), established in 1979 and headquartered in Frankfurt am Main, is Germany’s largest independent non-profit organization dedicated to combating cardiovascular diseases. With over 100,000 members, it serves as a vital resource for patients and the public, offering information on prevention, diagnosis, and treatment of heart conditions. Main objectives are to significantly reduce the incidence of cardiovascular diseases in Germany, enhance the quality of life for heart patients through education and support, promote early prevention, especially among children, to prevent the onset of heart diseases.

To achieve these goals, the German Heart Foundation organizes the annual Heart Weeks, a nationwide campaign in November featuring over 1,000 free informational events on specific heart conditions, publishes lay-language materials like the quarterly magazine “HERZ heute”, patient newsletters, and various brochures to disseminate expert knowledge, conducts preventive programs such as encouraging physical activity (“Skipping Hearts”) and resuscitation training in schools.

The German Heart Foundation is the founding body of the German Foundation for Heart Research (GFHR), which it set up to promote and fund research in cardiology. Both, GHF and GFHR, fund cardiovascular research by awarding scholarships, research projects and special research programmes (more than 6 Mio. Euros in 2024).

The GHF is supported by a Scientific Advisory Board comprising over 500 experts in cardiology, heart surgery, and paediatric cardiology and a large network of regional volunteers (mostly heart patients). It strongly collaborates with national and international organizations, including the German Society of Cardiology and the European Heart Network to fight for a national and international cardiovascular health plan.

Role in the project

Patients play a crucial role in enhancing the societal impact of research by actively engaging in its development and execution. By incorporating patients’ perspectives, experiences, and concerns, research initiatives become more comprehensive, realistic, and patient-centred.

The German Heart Foundation (DHS) contributes this vital perspective through its extensive network of patient experts. DHS not only supports the integration of patient voices in the project but also ensures that the broader patient community is informed and engaged throughout the study.

DHS is actively involved in the following Work Packages, where it advocates for the patient perspective and contributes through co-creation and engagement activities:

• WP3: Enabling Direct Patient Involvement through eHealth
• WP12: Stakeholder Engagement
• WP13: Dissemination and Communication

Through these contributions, DHS strengthens the relevance, inclusivity, and impact of the project.

Team

• Christine Dehn

About this partner

The Stiftung Institut für Herzinfarktforschung (Foundation IHF) was established in 2000 on the initiative of Professor Jochen Senges. According to its statutes, the purpose of the foundation is to promote clinical research in the field of cardiovascular diseases. The objective of the foundation is realized through scientific research into risk factors and causes of cardiovascular diseases, as well as possibilities for prophylaxis and patient care in the healthcare system. In addition, the foundation promotes cooperation between heart centers and the pharmaceutical and medical technology industries in order to successfully conduct clinical trials.

In the last 10 years, the focus of the work has been on the biometric evaluation of randomized studies relevant to guidelines. For this reason, statisticians at Foundation IHF have been involved in a large number of publications in high-level scientific journals (LANCET, New England Journal of Medicine). A total of around 50 publications are supported by Foundation IHF each year.

Role in the project

The Foundation IHF is responsible for all Work Packages of SGLT2 HYPE dealing with statistics. The Foundation will accompany the entire project, from the statistical planning in the protocol, the creation of the analysis programs, the conduct of all analyses to the support of the publications. Close cooperation with all consortium partners is essential for successful work.

Team

• Dr. Steffen Schneider
• Dr. Thomas Riemer
• Dr. Matthias Hochadel
• Dipl. Biol. Taoufik Ouarrak

About this partner

The Instituto de Investigación Sanitaria – Fundación Jiménez Díaz (IIS-FJD) is a leading biomedical research institution in Madrid, Spain, known for its commitment to scientific research, clinical innovation, and academic excellence. Affiliated with the Universidad Autónoma de Madrid (UAM), IIS-FJD enhances collaborative research and education, playing a key role in translating scientific findings into improved patient care.

Our group prioritizes public and patient outreach, sharing research outcomes widely. It is led by Dr. Borja Ibáñez, a leading cardiovascular researcher and Scientific Director at the Centro Nacional de Investigaciones Cardiovasculares (CNIC). Dr. Ibáñez holds four patents in cardiovascular treatment, has authored numerous high-impact publications, and contributed to several European Society of Cardiology guidelines, including coordinating those on acute myocardial infarction. He also serves on editorial boards of top international journals.

We are active in international research and often coordinate independent clinical trials. IIS-FJD also includes accredited researchers from other public hospitals in the Madrid region, strengthening its presence in biomedical research networks.

Our clinical trial unit is highly experienced, with strong ties to regional and national ethics committees, and a proven track record in managing European-level clinical trials.

Role in the project

Our organization will be responsible for the recruitment of patients in Spain, for leading the assessment of echocardiography acquisitions, performing a detailed analysis of the echocardiographic examinations during study visits at the other centres. As leader of the WP12 – Stakeholder engagement and exploitation – we will also take care of bringing together representatives from cardiological societies, European HTA bodies and patient organisations. Finally, this engagement with relevant societies will make it possible to formulate recommendations for guideline revision and implement the project results in hypertension guidelines.

Team

• Prof. Dr. Borja Ibáñez Cabeza, MD PhD FESC.
• Dr. Jose Antonio Esteban Chapel, MD.Dr. Sandra Gómez Talavera, MD PhD.
• Dr. Miguel Orejas Orejas, MD PhD.
• Dr. Mikel Taibo Urquia, MD.
• Dr. Marcelino Cortés García, MD PhD.
• Dr. Miguel Angel Navas Lobato, MD.
• Dr. Mónica Recio Vázquez, MD.
• Dr. Carlos de Cabo Porras, MD.
• Dr. Jaime Francisco Larre Guerre, MD.
• Dr. Alvaro Castrillo Capilla, MD.
• Dr. Macarena Garbayo Bugeda, MD.
• Alba Vega Villuela (SN/SC)
• Carlos Prados Hidalgo (SN/SC)
• María López Álvarez (SN/SC)

About this partner

Inserm is the only public research organization in France entirely dedicated to health.

The institute is involved in the entire range of activities from the laboratory to the patient’s bedside. It also partners with the most prestigious research institutions in the world that are committed to scientific challenges and progress in these fields.

Role in the project

INSERM is the leader of WP4 – Set up and initiation of the biobank and together with UPORTO will implement WP11 – Mechanistic studies of SGLT2i in HTN by

biomarker analysis. The WPs focus on understanding how the SGLT2-inhibitor (SGLT2i) treatment works at the biological level and exploring ways to personalize treatment in the future.
Our objective: to promote the health of all by advancing knowledge on living organisms and their diseases, and by developing innovation.

Team

• Prof. Nicolas Girerd
• Celine Leroy

About this partner

The IRCCS Azienda Ospedaliero-Universitaria di Bologna (IRCCS AOUBO) is the first hospital in Bologna municipality, with over 400 years of history and it is the official headquarters of the School of Medicine and Surgery of the University of Bologna, being the University’s reference centre for healthcare activities crucial for academic education, training and clinical research.

IRCCS AOUBO is a multi-specialistic and highly specialized hospital, distributed over 32 pavilions, with a total of 1.498 beds. The hospital is staffed with 5.944 employees including university researchers and physicians. IRCCS AOUBO is a tertiary referral hospital managing thousands of patients from Emilia-Romagna, other Italian regions, and European and non-European countries. The IRCCS AOUBO was award in 2020 the title of “IRCCS – Istituto di Ricovero e Cura a Carattere Scientifico” by the Italian Ministry of Health, as the result of high specialization and excellence in care and biomedical research at national, regional and local level, with the main purpose of guaranteeing answers to health needs
– through the provision of highly specialized hospitalization and care services
– through the development of clinical and translational research projects aimed at improving the population’s state of health.

IRCCS AOUBO has extensive expertise in the management of patients and has suited with clinical and technical personnel trained for the performance and management of clinical trials from T1 to T4.

Role in the project

IRCCS AOUBO is involved in the conduction of the clinical study and will act as Italian coordinating centre supporting the fine management of the study conduct with all the Italian satellite centres. The site will act at enrolment site and collaborate with the clinical coordinator contributing at the monitoring of the overall recruitment efforts within the country and, support the coordinator in identifying and implementing solutions to grant the study conduct within the planned timeline, and the obtaining of the study objectives. IRCCS AOUBO will also support the development of a patient recruitment strategy (WP12).

Team

• Prof. Luciano Potena
• Dr. Antonio Russo
• Laura Borgese
• Dr. Alberto Foà

About this partner

Vilnius University Hospital Santaros Klinikos is one of Lithuania’s leading medical institutions, located in Vilnius. It provides advanced, multidisciplinary care through seven clinical groups and 35 specialized centers, including surgery, cardiology, oncology, and pediatrics. The hospital is staffed by over 8,000 professionals and works closely with Vilnius University’s Faculty of Medicine, serving as a hub for clinical research and the training of future healthcare leaders.

Santaros Klinikos is renowned for its expertise in complex treatments, offering services such as minimally invasive and robotic surgeries, organ and stem cell transplants, and CAR T-cell therapy. The hospital also participates in several European Reference Networks for rare diseases, ensuring high-quality care for patients with complex conditions. Additionally, it excels in digital health, equipped with a robust electronic health record system and biobanking services that support both patient care and research.

Recent expansions at Santaros Klinikos include new divisions for odontology and maxillofacial surgery, as well as the establishment of an Advanced Therapy Center and a modern Emergency Department. Guided by the vision “Innovating today to lead the healthcare of tomorrow,” Santaros Klinikos is committed to advancing healthcare in the Baltic region.

Role in the project

Vilnius University Hospital Santaros Klinikos (VULSK) plays a collaborative role in the SGLT2 HYPE project, contributing to several key work packages. VULSK is involved in regulatory framework alignment (WP1), is responsible for the  patient recruitment in Lithuania (WP6), and will also support the development of a patient recruitment strategy (WP12).

Additionally, Dr. Rokas Serpytis from VULSK is part of the internal Investigator Board, which provides strategic guidance to ensure scientific and ethical rigor across the trial.

Team

• Dr. Rokas Šerpytis
• Aurelija Ruškienė
• Alicja Čepulionis
• Rūta Goštautaitė

About this partner

The General Practitioners Research Institute aims to improve the lives of patients. We develop and facilitate research on the prevention, diagnosis, and treatment of diseases in primary care. GPRI performs scientific research in primary care by making it accessible and enjoyable for all. Based on the results of our studies, guidelinesfor primary care can be based on patients from primary care. We have a worldwide network of primary care centers involving GP practices and pharmacies. Additionally our extensive global network of Key Opinion Leaders help us guard the quality and impact of our studies, as well as strengthen partnerships and drive innovation.

Role in the project

Facilitating inclusion in Dutch primary care practices (WP6) and supporting the development of a recruitment strategy (WP12).

Team

• Prof. Dr. Janwillem W.H. Kocks and team

About this partner

The National Institute of Cardiology Stefan Cardinal Wyszyński (NIKARD) is one of Poland’s premier centers for cardiology and cardiac surgery, holding the highest Level IV reference status. As a nationally recognized leader, NIKARD plays a key role in postgraduate cardiology education and serves as a dynamic hub for innovative scientific and clinical research.

For decades, the Institute has been consistently ranked among the top medical institutions in Poland, widely acknowledged for developing and implementing cutting-edge methods in cardiovascular treatment and rehabilitation. NIKARD is also strongly committed to cardiovascular disease prevention and health promotion. It leads nationwide programs to monitor the incidence and progression of cardiovascular diseases across the Polish population—initiatives essential to shaping effective public health strategies.

Through a wide range of scientific studies, development initiatives, and clinical trials, NIKARD continues to advance the fields of cardiology and cardiac surgery, improve patient outcomes, and support the long-term health of communities in Poland and beyond.

Role in the project

The National Institute of Cardiology (NIKARD) is a partner in the project, ensuring full compliance with local regulations and international medical, ethical, and scientific standards. It is responsible for recruiting patients in Poland, for the delivery of advanced treatments, and management of follow-up visits according to the approved study protocol. Strict adherence to these standards ensures the protection of participants’ rights and safety, as well as the integrity and reliability of the collected data. Additionally, the Institute incorporates gender and socio-demographic factors into its analyses to provide a comprehensive and inclusive evaluation of study outcomes. NIKARD will also support the development of a patient recruitment strategy (WP12).

Team

• Prof. Janina Stępinska
• Dr. Katarzyna Paschalis-Purtak
• Dr. Bogna Puciłowska-Jankowska

About this partner

The Faculty of Medicine of the University of Porto is one of the most prestigious national higher education institutions, recognized for the quality of its educational offer, leading position in the production of medical-scientific research and the symbiotic link with more than 20 health institutions. In the last 5 years, FMUP has raised around 22M€ in competitive tenders, ensuring the funding of 134 scientific projects, 40 of which were international. UPORTO also promoted 1,159 clinical studies and produced 7,260 articles in WoS-indexed journals (86 Highly Cited articles and 2 Hot Papers), 39% of which were published in Q1 journals. These articles were the basis of more than 66,000 citations, helping the institution to stand out in areas such as Cardiovascular Diseases, Internal Medicine, Biochemistry and Molecular Biology, Gastroenterology and Public Health. Distinctively, FMUP integrates the first Associate Laboratory dedicated to clinical and translational research – RISE – and also hosts the country’s largest R&D unit in the same area – RISE-Health, the result of an unprecedented merger and the unanimous strategic will of the leaders and researchers of 4 former R&D units, increasing critical mass, greater multidisciplinary and interdisciplinary synergies, and scientific complementarity. In this context, UPORTO is at the forefront of clinical and translational research in Portugal.

Role in the project

In WP4, led by INSERM, UPORTO participates in establishing SOPs for blood sample collection, storage, and shipment, ensuring standardised procedures for the SGLT2 HYPE biobank.
UPORTO, together with INSERM, leads the mechanistic studies of SGLT2i in HTN through biomarker analysis (WP11).
UPORTO is also involved in the design of the clinical trial and statistical analyses (WP5),is responsible for patient recruitment in Portugal (WP6) and supports the development of a patient recruitment strategy (WP12).

Team

• Prof. Dr. João Pedro Ferreira
• Prof. Dr. Adelino Leite Moreira
• Dr. Francisco Vasques-Nóvoa
• Dr. Pedro Marques
• Dr. Francisca Saraiva
• Dr. Isabel Miranda

About this partner

With over 8,300 employees, University Medical Centre Ljubljana is one of Slovenia’s largest and most advanced healthcare institutions. Known for its excellence in care, UMCL is comparable to leading hospitals in Europe and globally. It is the only hospital in Slovenia offering specialized care for certain diseases. UKCL follows a triple mission of healthcare, education, and research, with a strong commitment to safe, high-quality, and standardized patient care.

To enhance service efficiency and effectiveness, UKCL applies clinical care pathways and actively seeks international accreditations, including the national Business Excellence Award based on the EFQM model. While leading in medical services, UKCL also values compassion, care, and a personal approach.

UKCL serves patients from across Slovenia and abroad, striving daily to maintain the highest standards of care and safety. Its core mission is to deliver top-tier healthcare and support the development of Slovenia’s health system across all specialties.

The Department of Hypertension is part of the Division of Internal Medicine and is located in Bolnica dr. Petra Držaja. And includes a hospital ward, outpatient clinic, and non-invasive cardiology diagnostics. The department specializes in managing resistant arterial hypertension and other cardiovascular conditions and is recognized by the European Hypertension Society as an Excellence Centre.

Role in the project

The department of Hypertension of UKCL will be responsible for the recruitment and follow up of the patients in Slovenia and will support the development of a patient recruitment strategy (WP12).

Team

• Assoc. Prof. Dr. Jana Brguljan Hitij
• MD. Nina Božič Ješe
• Dr. Judita Knez

About this partner

Bogomolets National Medical University (BNMU) is the leading medical university in Ukraine, which history dates back since 1841. BNMU possesses educational and clinical facilities for conducting high quality training of medical students. It comprises 10 faculties and institutes, including Faculty for training of foreign citizens and Institute of post-graduate education. It is the core centre for academic fundamental investigations and clinical practices with ongoing research works of over 550 PhD and Doctor of Medical Science candidates. The University Clinic of BNMU provides consulting, diagnostic and inpatient medical care to the public. The inpatient unit of the clinic consists of multidisciplinary and multifunctional team of specialists from 11 departments, which have all the necessary facilities for diagnosis, treatment and round-the-clock patient monitoring. Professors at BNMU are among the first ones to implement advanced technologies in pedagogical sphere and patients management in Ukraine. BNMU is always in the top of different ranking systems among all universities in Ukraine.

Role in the project

BNMU is responsible for administrative communication on SGLT2 HYPE clinical trial in Ukraine, patients recruitment, consenting and patients management according to the protocol and other study-specific documents. Internal medicine specialists and cardiologists from BNMU will provide clinical assessment of the patients and data entrance into applicable systems of the study. They will evaluate the obtained results with further publication in the form of scientific articles and provide input to updates of international guidelines on arterial hypertension management. BNMU will also support the development of a patient recruitment strategy (WP12).

Team

• Sergii Zemskov, MD, Vice-Rector for Research and Innovations, Doctor of Medical Sciences, Professor –  Legal Entity Appointed Representative;
• Vasyl Netiazhenko, MD, Head of Department of Propedeutics of Internal Medicine № 1, Corresponding Member of NAMS of Ukraine, Doctor of Medical Sciences, Professor – Principal Investigator;
• Tetiana Malchevska, MD, Doctor of Medical Sciences, Professor of Department Propedeutics of Internal Medicine № 1 – Sub-Investigator;
• Oksana Rekovets, MD, Doctor of Medical Sciences, Assistant Professor of Department Propedeutics of Internal Medicine № 1 – Sub-Investigator;
• Yana Himanova, MD, Senior Assistant, PhD candidate of Department Propedeutics of Internal Medicine № 1 – study team member;
• Anna Blagaia, MD, PhD, Associate Professor of Department of Hygiene and Ecology – technical coordinator.

About this partner

Founded in 1451, the University of Glasgow is the fourth oldest university in the English-speaking world. The University of Glasgow

• is ranked 78th in the world in the QS World University Rankings 2025
• in the top 100 in the world: Times Higher World University Rankings 2024
• Scottish University of the Year in The Times & The Sunday Times Good University Guide 2024
• welcomes students from >140 countries with ~35,000 undergraduate and postgraduate students
• has a global community of almost 300,000 alumni
• employs >11,000 staff, including >5,100 research and teaching staff
• undertaking a £1 billion estate investment to expand campus research & teaching facilities
• annual research income of >£200m
• member of the prestigious Russell Group of leading UK research universities
• founding member of Universitas 21, an international group of universities dedicated to setting worldwide standards for higher education
• founding member of The Guild of European Research Intensive Universities
• strategic partnerships with the Universities of Columbia, Hong Kong, McGill and Sydney
• home to The Hunterian Museum and Art Gallery
• partners with the Singapore Institute of Technology, Nankai University and the University of Electronic Science & Technology of China
• includes among its alumni, the father of economics Adam Smith, Scotland’s architect of devolution Donald Dewar and renowned physicist and engineer Lord Kelvin.
• ranked 12th in the world for THE Impact Rankings UN’s Sustainable Development Goals SDG1: No Poverty – 22nd , SDG11: Sustainable Cities & Communities – 9th , SDG15: Life on Land – 12th

Role in the project

Providing expertise in the design, conduct and interpretation of randomised trials and expert advice on primary and secondary clinical endpoints. Providing advice and support for health-economic evaluations. Expert writing skills for scientific manuscripts.

Team

• Prof. Dr. John GF Cleland